nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—Basal cell carcinoma—Octreotide—thymus cancer	0.0709	0.11	CcSEcCtD
Pimecrolimus—Ear infection—Octreotide—thymus cancer	0.0393	0.061	CcSEcCtD
Pimecrolimus—Loose stools—Octreotide—thymus cancer	0.0302	0.0468	CcSEcCtD
Pimecrolimus—MTOR—neck—thymus cancer	0.0278	0.0946	CbGeAlD
Pimecrolimus—FKBP1A—neck—thymus cancer	0.025	0.0851	CbGeAlD
Pimecrolimus—Throat sore—Octreotide—thymus cancer	0.0232	0.036	CcSEcCtD
Pimecrolimus—Oropharyngeal discomfort—Octreotide—thymus cancer	0.023	0.0357	CcSEcCtD
Pimecrolimus—Otitis media—Octreotide—thymus cancer	0.0215	0.0333	CcSEcCtD
Pimecrolimus—MTOR—hematopoietic system—thymus cancer	0.0207	0.0704	CbGeAlD
Pimecrolimus—Acne—Octreotide—thymus cancer	0.0199	0.0308	CcSEcCtD
Pimecrolimus—Neoplasm malignant—Octreotide—thymus cancer	0.0196	0.0304	CcSEcCtD
Pimecrolimus—MTOR—epithelium—thymus cancer	0.0189	0.0644	CbGeAlD
Pimecrolimus—FKBP1A—hematopoietic system—thymus cancer	0.0186	0.0633	CbGeAlD
Pimecrolimus—Viral infection—Octreotide—thymus cancer	0.0185	0.0287	CcSEcCtD
Pimecrolimus—Oropharyngeal pain—Octreotide—thymus cancer	0.0184	0.0285	CcSEcCtD
Pimecrolimus—Herpes simplex—Octreotide—thymus cancer	0.0181	0.0281	CcSEcCtD
Pimecrolimus—FKBP1A—epithelium—thymus cancer	0.017	0.0579	CbGeAlD
Pimecrolimus—Influenza like illness—Octreotide—thymus cancer	0.0162	0.0252	CcSEcCtD
Pimecrolimus—Wheezing—Octreotide—thymus cancer	0.0162	0.0252	CcSEcCtD
Pimecrolimus—MTOR—pituitary gland—thymus cancer	0.0153	0.0522	CbGeAlD
Pimecrolimus—MTOR—lymphoid tissue—thymus cancer	0.0146	0.0496	CbGeAlD
Pimecrolimus—FKBP1A—cardiac atrium—thymus cancer	0.0141	0.0481	CbGeAlD
Pimecrolimus—FKBP1A—pituitary gland—thymus cancer	0.0138	0.047	CbGeAlD
Pimecrolimus—Gastroenteritis—Octreotide—thymus cancer	0.0137	0.0212	CcSEcCtD
Pimecrolimus—Nasal congestion—Octreotide—thymus cancer	0.0133	0.0207	CcSEcCtD
Pimecrolimus—MTOR—bone marrow—thymus cancer	0.0133	0.0451	CbGeAlD
Pimecrolimus—MTOR—thyroid gland—thymus cancer	0.0132	0.045	CbGeAlD
Pimecrolimus—FKBP1A—lymphoid tissue—thymus cancer	0.0131	0.0446	CbGeAlD
Pimecrolimus—MTOR—lung—thymus cancer	0.012	0.0409	CbGeAlD
Pimecrolimus—FKBP1A—bone marrow—thymus cancer	0.0119	0.0406	CbGeAlD
Pimecrolimus—FKBP1A—thyroid gland—thymus cancer	0.0119	0.0405	CbGeAlD
Pimecrolimus—Abdominal pain upper—Octreotide—thymus cancer	0.0111	0.0172	CcSEcCtD
Pimecrolimus—Nasopharyngitis—Octreotide—thymus cancer	0.0108	0.0168	CcSEcCtD
Pimecrolimus—FKBP1A—lung—thymus cancer	0.0108	0.0368	CbGeAlD
Pimecrolimus—Asthma—Octreotide—thymus cancer	0.0105	0.0163	CcSEcCtD
Pimecrolimus—Influenza—Octreotide—thymus cancer	0.0105	0.0163	CcSEcCtD
Pimecrolimus—Bronchitis—Octreotide—thymus cancer	0.0101	0.0156	CcSEcCtD
Pimecrolimus—Upper respiratory tract infection—Octreotide—thymus cancer	0.00975	0.0151	CcSEcCtD
Pimecrolimus—Pneumonia—Octreotide—thymus cancer	0.0094	0.0146	CcSEcCtD
Pimecrolimus—Conjunctivitis—Octreotide—thymus cancer	0.00909	0.0141	CcSEcCtD
Pimecrolimus—Epistaxis—Octreotide—thymus cancer	0.00882	0.0137	CcSEcCtD
Pimecrolimus—Sinusitis—Octreotide—thymus cancer	0.00877	0.0136	CcSEcCtD
Pimecrolimus—Rhinitis—Octreotide—thymus cancer	0.00842	0.0131	CcSEcCtD
Pimecrolimus—Pharyngitis—Octreotide—thymus cancer	0.00833	0.0129	CcSEcCtD
Pimecrolimus—MTOR—lymph node—thymus cancer	0.00821	0.028	CbGeAlD
Pimecrolimus—Flushing—Octreotide—thymus cancer	0.00779	0.0121	CcSEcCtD
Pimecrolimus—Immune system disorder—Octreotide—thymus cancer	0.00758	0.0118	CcSEcCtD
Pimecrolimus—FKBP1A—lymph node—thymus cancer	0.00738	0.0252	CbGeAlD
Pimecrolimus—Erythema—Octreotide—thymus cancer	0.00731	0.0113	CcSEcCtD
Pimecrolimus—Malnutrition—Octreotide—thymus cancer	0.00731	0.0113	CcSEcCtD
Pimecrolimus—Back pain—Octreotide—thymus cancer	0.00707	0.011	CcSEcCtD
Pimecrolimus—Cough—Octreotide—thymus cancer	0.00638	0.00989	CcSEcCtD
Pimecrolimus—Arthralgia—Octreotide—thymus cancer	0.00622	0.00965	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.00618	0.00958	CcSEcCtD
Pimecrolimus—CYP3A4—hematopoietic system—thymus cancer	0.00607	0.0207	CbGeAlD
Pimecrolimus—Anaphylactic shock—Octreotide—thymus cancer	0.00596	0.00925	CcSEcCtD
Pimecrolimus—Oedema—Octreotide—thymus cancer	0.00596	0.00925	CcSEcCtD
Pimecrolimus—Infection—Octreotide—thymus cancer	0.00592	0.00919	CcSEcCtD
Pimecrolimus—Nervous system disorder—Octreotide—thymus cancer	0.00585	0.00907	CcSEcCtD
Pimecrolimus—Skin disorder—Octreotide—thymus cancer	0.00579	0.00899	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Octreotide—thymus cancer	0.00543	0.00843	CcSEcCtD
Pimecrolimus—Paraesthesia—Octreotide—thymus cancer	0.00535	0.00831	CcSEcCtD
Pimecrolimus—Dyspnoea—Octreotide—thymus cancer	0.00532	0.00825	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Octreotide—thymus cancer	0.00515	0.00799	CcSEcCtD
Pimecrolimus—Pain—Octreotide—thymus cancer	0.0051	0.00791	CcSEcCtD
Pimecrolimus—Constipation—Octreotide—thymus cancer	0.0051	0.00791	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Octreotide—thymus cancer	0.00488	0.00757	CcSEcCtD
Pimecrolimus—Urticaria—Octreotide—thymus cancer	0.00474	0.00735	CcSEcCtD
Pimecrolimus—Abdominal pain—Octreotide—thymus cancer	0.00471	0.00731	CcSEcCtD
Pimecrolimus—Body temperature increased—Octreotide—thymus cancer	0.00471	0.00731	CcSEcCtD
Pimecrolimus—Hypersensitivity—Octreotide—thymus cancer	0.00439	0.00682	CcSEcCtD
Pimecrolimus—Pruritus—Octreotide—thymus cancer	0.00422	0.00655	CcSEcCtD
Pimecrolimus—Diarrhoea—Octreotide—thymus cancer	0.00408	0.00633	CcSEcCtD
Pimecrolimus—Vomiting—Octreotide—thymus cancer	0.00379	0.00588	CcSEcCtD
Pimecrolimus—Rash—Octreotide—thymus cancer	0.00376	0.00583	CcSEcCtD
Pimecrolimus—Dermatitis—Octreotide—thymus cancer	0.00376	0.00583	CcSEcCtD
Pimecrolimus—Headache—Octreotide—thymus cancer	0.00374	0.0058	CcSEcCtD
Pimecrolimus—Nausea—Octreotide—thymus cancer	0.00354	0.0055	CcSEcCtD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—thymus cancer	0.00293	0.0473	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD8A—thymus cancer	0.00174	0.0281	CbGpPWpGaD
Pimecrolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—thymus cancer	0.00136	0.0219	CbGpPWpGaD
Pimecrolimus—FKBP1A—TOR Signaling—AKT1—thymus cancer	0.00134	0.0216	CbGpPWpGaD
Pimecrolimus—MTOR—CD28 dependent PI3K/Akt signaling—AKT1—thymus cancer	0.00116	0.0187	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD4—thymus cancer	0.001	0.0162	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—thymus cancer	0.000981	0.0158	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL2—thymus cancer	0.000953	0.0154	CbGpPWpGaD
Pimecrolimus—MTOR—FSH signaling pathway—AKT1—thymus cancer	0.000945	0.0153	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL2—thymus cancer	0.00092	0.0149	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFR2 mediated vascular permeability—AKT1—thymus cancer	0.000918	0.0148	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—CD4—thymus cancer	0.000905	0.0146	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—KIT—thymus cancer	0.000883	0.0143	CbGpPWpGaD
Pimecrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—AKT1—thymus cancer	0.000869	0.014	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—KIT—thymus cancer	0.000862	0.0139	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—KIT—thymus cancer	0.000856	0.0138	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—thymus cancer	0.000836	0.0135	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—IL2—thymus cancer	0.000833	0.0135	CbGpPWpGaD
Pimecrolimus—MTOR—CD28 co-stimulation—AKT1—thymus cancer	0.000825	0.0133	CbGpPWpGaD
Pimecrolimus—MTOR—Alpha 6 Beta 4 signaling pathway—AKT1—thymus cancer	0.000805	0.013	CbGpPWpGaD
Pimecrolimus—MTOR—LKB1 signaling events—TP53—thymus cancer	0.000772	0.0125	CbGpPWpGaD
Pimecrolimus—MTOR—Class I PI3K signaling events mediated by Akt—AKT1—thymus cancer	0.000768	0.0124	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CD4—thymus cancer	0.000764	0.0123	CbGpPWpGaD
Pimecrolimus—MTOR—TOR Signaling—AKT1—thymus cancer	0.000751	0.0121	CbGpPWpGaD
Pimecrolimus—MTOR—IL2 signaling events mediated by PI3K—AKT1—thymus cancer	0.000735	0.0119	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR3-mediated signaling events—AKT1—thymus cancer	0.000719	0.0116	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—thymus cancer	0.000679	0.011	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB2/ErbB3 signaling events—AKT1—thymus cancer	0.000677	0.0109	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—KIT—thymus cancer	0.00066	0.0107	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—AKT1—thymus cancer	0.000652	0.0105	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB Signaling Pathway—TP53—thymus cancer	0.000643	0.0104	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—KIT—thymus cancer	0.000632	0.0102	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—KIT—thymus cancer	0.000622	0.01	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TP53—thymus cancer	0.000612	0.00988	CbGpPWpGaD
Pimecrolimus—MTOR—TSLP Signaling Pathway—AKT1—thymus cancer	0.000607	0.0098	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—KIT—thymus cancer	0.000594	0.00959	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—KIT—thymus cancer	0.000591	0.00955	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—KIT—thymus cancer	0.000588	0.0095	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—KIT—thymus cancer	0.000585	0.00945	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CYLD—thymus cancer	0.000583	0.00942	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—thymus cancer	0.000577	0.00932	CbGpPWpGaD
Pimecrolimus—MTOR—Wnt Signaling Pathway Netpath—AKT1—thymus cancer	0.00056	0.00904	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—thymus cancer	0.000554	0.00896	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—KIT—thymus cancer	0.000551	0.00889	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—KIT—thymus cancer	0.000551	0.00889	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—thymus cancer	0.000551	0.00889	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—KIT—thymus cancer	0.000546	0.00881	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—KIT—thymus cancer	0.000541	0.00873	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—KIT—thymus cancer	0.000538	0.0087	CbGpPWpGaD
Pimecrolimus—MTOR—RANKL/RANK Signaling Pathway—AKT1—thymus cancer	0.000535	0.00864	CbGpPWpGaD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—AKT1—thymus cancer	0.000535	0.00864	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—TP53—thymus cancer	0.000529	0.00854	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—KIT—thymus cancer	0.000509	0.00823	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—thymus cancer	0.000488	0.00788	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—AKT1—thymus cancer	0.000486	0.00785	CbGpPWpGaD
Pimecrolimus—MTOR—Oncostatin M Signaling Pathway—AKT1—thymus cancer	0.000468	0.00756	CbGpPWpGaD
Pimecrolimus—MTOR—mTOR signaling pathway—AKT1—thymus cancer	0.000462	0.00747	CbGpPWpGaD
Pimecrolimus—MTOR—TSH signaling pathway—AKT1—thymus cancer	0.000462	0.00747	CbGpPWpGaD
Pimecrolimus—MTOR—Costimulation by the CD28 family—AKT1—thymus cancer	0.000452	0.00729	CbGpPWpGaD
Pimecrolimus—MTOR—Regulation of Telomerase—AKT1—thymus cancer	0.000452	0.00729	CbGpPWpGaD
Pimecrolimus—MTOR—AMPK Signaling—AKT1—thymus cancer	0.000446	0.00721	CbGpPWpGaD
Pimecrolimus—MTOR—SREBP signalling—AKT1—thymus cancer	0.000446	0.00721	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—MAML2—thymus cancer	0.000443	0.00716	CbGpPWpGaD
Pimecrolimus—MTOR—Leptin signaling pathway—AKT1—thymus cancer	0.000418	0.00674	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	0.000416	0.00672	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—thymus cancer	0.000397	0.0064	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thymus cancer	0.000381	0.00616	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—AKT1—thymus cancer	0.000381	0.00616	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—thymus cancer	0.000378	0.0061	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—KIT—thymus cancer	0.000375	0.00606	CbGpPWpGaD
Pimecrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thymus cancer	0.000374	0.00604	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	0.000351	0.00568	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CYLD—thymus cancer	0.00034	0.00549	CbGpPWpGaD
Pimecrolimus—MTOR—PI-3K cascade—AKT1—thymus cancer	0.000337	0.00545	CbGpPWpGaD
Pimecrolimus—MTOR—PI3K/AKT activation—AKT1—thymus cancer	0.000329	0.00532	CbGpPWpGaD
Pimecrolimus—MTOR—GAB1 signalosome—AKT1—thymus cancer	0.000326	0.00527	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—CDKN2A—thymus cancer	0.000325	0.00524	CbGpPWpGaD
Pimecrolimus—MTOR—ErbB1 downstream signaling—AKT1—thymus cancer	0.000319	0.00515	CbGpPWpGaD
Pimecrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	0.000319	0.00515	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—thymus cancer	0.000314	0.00508	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—MAML2—thymus cancer	0.00031	0.00501	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—AKT1—thymus cancer	0.000297	0.00479	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—thymus cancer	0.000282	0.00456	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD8A—thymus cancer	0.000274	0.00442	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—AKT1—thymus cancer	0.000252	0.00407	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—MAML2—thymus cancer	0.000249	0.00402	CbGpPWpGaD
Pimecrolimus—MTOR—BDNF signaling pathway—AKT1—thymus cancer	0.000248	0.004	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—thymus cancer	0.000241	0.00389	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—thymus cancer	0.000239	0.00385	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—AKT1—thymus cancer	0.000237	0.00383	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin Signaling—AKT1—thymus cancer	0.000228	0.00368	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—AKT1—thymus cancer	0.000227	0.00366	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—AKT1—thymus cancer	0.000225	0.00364	CbGpPWpGaD
Pimecrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	0.000225	0.00364	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—AKT1—thymus cancer	0.000224	0.00362	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—AKT1—thymus cancer	0.000223	0.00361	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	0.00022	0.00355	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—KIT—thymus cancer	0.000214	0.00346	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	0.00021	0.00339	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—AKT1—thymus cancer	0.00021	0.00339	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—AKT1—thymus cancer	0.00021	0.00339	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—AKT1—thymus cancer	0.000208	0.00336	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—thymus cancer	0.000206	0.00333	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—AKT1—thymus cancer	0.000205	0.00332	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—KIT—thymus cancer	0.000205	0.00332	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—KIT—thymus cancer	0.000205	0.0033	CbGpPWpGaD
Pimecrolimus—MTOR—B Cell Activation—AKT1—thymus cancer	0.000194	0.00314	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	0.000186	0.00301	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—TP53—thymus cancer	0.000181	0.00292	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—MAML2—thymus cancer	0.000174	0.00282	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD8A—thymus cancer	0.000166	0.00268	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD4—thymus cancer	0.000164	0.00264	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD4—thymus cancer	0.000157	0.00254	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD4—thymus cancer	0.000156	0.00253	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—KIT—thymus cancer	0.000143	0.00231	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—AKT1—thymus cancer	0.000143	0.00231	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—KIT—thymus cancer	0.000125	0.00201	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—KIT—thymus cancer	0.000115	0.00186	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—thymus cancer	0.000101	0.00163	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—thymus cancer	9.53e-05	0.00154	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—thymus cancer	8.8e-05	0.00142	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—thymus cancer	8.77e-05	0.00142	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—AKT1—thymus cancer	8.16e-05	0.00132	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—KIT—thymus cancer	8.05e-05	0.0013	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—AKT1—thymus cancer	7.84e-05	0.00127	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—AKT1—thymus cancer	7.8e-05	0.00126	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—TP53—thymus cancer	6.47e-05	0.00105	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—thymus cancer	5.67e-05	0.000916	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—AKT1—thymus cancer	5.46e-05	0.000883	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—AKT1—thymus cancer	4.75e-05	0.000768	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—AKT1—thymus cancer	4.39e-05	0.000709	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—TP53—thymus cancer	3.64e-05	0.000588	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—AKT1—thymus cancer	3.07e-05	0.000496	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AKT1—thymus cancer	9.75e-06	0.000157	CbGpPWpGaD
